Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: CAMP camp4tx.com
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression to restore healthy protein levels for the treatment of genetic diseases. The company's proprietary RAP Platform enables the mapping of regulatory RNAs (regRNAs) and generation of therapeutic antisense oligonucleotide (ASO) drug candidates targeting regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200. The company's lead program, CMP-002, targets SYNGAP1-related disorder, a rare neurological condition with no approved disease-modifying treatments. CAMP4 has received regulatory clearance in Australia and Argentina to initiate a Phase 1/2 clinical trial of CMP-002 and has submitted filings in the EU and UK. The company trades on Nasdaq under the ticker CAMP. Updated
Wednesday’s top analyst upgrades and downgrades included Apple, Carvana, Elanco Animal Health, Gilead Sciences, Home Depot, Park Hotels & Resorts, Shoals Technologies, SNDL, SITE Centers and UDR.
Thursday's top analyst upgrades and downgrades included AT&T, Abbott Laboratories, Advanced Micro Devices, Affirm, Canopy Growth, Cleanspark, Eli Lilly, ESS Tech, Global Payments and Luminar Technologies.
Friday’s top analyst upgrades and downgrades included APA, Arcturus, CME, Darden, First Solar, Logitech, Netflix Nike, Nokia, Sea, and more.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Allstate, CalAmp, Chubb, Costco, Esperion Therapeutics, Flex, Hartford Financial Services, Nio, Rockwell Automation and Roku.
The top analyst upgrades, downgrades and initiations seen on Monday included Akamai Technologies, Analog Devices, Enphase Energy, LivePerson, NCR, Nu Skin, Tiffany and Valero Energy.
The top analyst upgrades, downgrades and initiations seen on Friday included Avaya, AstraZeneca, HD Supply, HubSpot, Intel, Norfolk Southern, Ultimate Software and Valero Energy.
The top analyst upgrades, downgrades and other research calls from Friday included Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike and NXP Semiconductors.
The top analyst upgrades, downgrades and other research calls from Thursday include American Water Works, Berkshire Hathaway, Booking, CRISPR Therapeutics, Dollar Tree, U.S. Steel and Whiting Petroleum.
The op analyst upgrades, downgrades and other research calls from Thursday include Abbott Labs, Amazon, CME, Foot Locker, GE, Home Depot and Lam Research.
The top analyst upgrades, downgrades and other research calls from Monday include CalAmp, Fiat Chrysler, Lowe's, Plains All American and Ulta Beauty.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Amazon.com, American Express, Best Buy, General Electric, JPMorgan, Wells Fargo and Conagra Brands.
There are some companies hitting lows and creating huge shareholder losses while the market is just below all-time highs. These are the same companies holding back the market and destroying shareholders.
CalAmp shares tumbled early on Friday after it released its fiscal second-quarter financial results late on Thursday.
Chris Lange Under the terms of the deal, CalAmp will acquire all of the outstanding shares of common stock of LoJack in an all cash transaction valued at approximately $134 million.
Chris Lange CalAmp has announced a bid to acquire LoJack in a transaction valued at approximately $113 million.
Chris Lange CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression to restore healthy protein levels for the treatment of genetic diseases.
The Wall Street consensus 12-month price target for CAMP is $10.57.
